MOOD-STABILIZING AGENTS
Four mood stabilizers in common use: lithium, valproic acid, carbamazepine/oxcarbazepine, and lamotrigine (Table 200-4). Lithium is the gold standard and the best studied, and along with carbamazepine and valproic acid, is used for treatment of acute manic episodes; 1–2 weeks to reach full effect. As prophylaxis, the mood stabilizers reduce frequency and severity of both manic and depressed episodes in cyclical mood disorders. In refractory bipolar disorder, combinations of mood stabilizers may be beneficial.
AGENT AND DOSING | SIDE EFFECTS AND OTHER EFFECTS |
---|---|
Lithium | Common Side Effects |
Starting dose: 300 mg bid or tid Therapeutic blood level: 0.8–1.2 meq/L | Nausea/anorexia/diarrhea, fine tremor, thirst, polyuria, fatigue, weight gain, acne, folliculitis, neutrophilia, hypothyroidism Blood level is increased by thiazides, tetracyclines, and NSAIDs Blood level is decreased by bronchodilators, verapamil, and carbonic anhydrase inhibitors Rare side effects: Neurotoxicity, renal toxicity, hypercalcemia, ECG changes |
Valproic Acid | Common Side Effects |
Starting dose: 250 mg tid Therapeutic blood level: 50–125 µg/mL | Nausea/anorexia, weight gain, sedation, tremor, rash, alopecia Inhibits hepatic metabolism of other medications Rare side effects: Pancreatitis, hepatotoxicity, Stevens-Johnson syndrome |
Carbamazepine/Oxcarbazepine | Common Side Effects |
Starting dose: 200 mg bid for carbamazepine, 150 mg bid for oxcarbazepine Therapeutic blood level: 4–12 µg/mL for carbamazepine | Nausea/anorexia, sedation, rash, dizziness/ataxia Carbamazepine, but not oxcarbazepine, induces hepatic metabolism of other medications Rare side effects: Hyponatremia, agranulocytosis, Stevens-Johnson syndrome |
Lamotrigine | Common Side Effects |
Starting dose: 25 mg/d | Rash, dizziness, headache, tremor, sedation, nausea Rare side effect: Stevens-Johnson syndrome |
Abbreviations: ECG, electrocardiogram; NSAIDs, nonsteroidal anti-inflammatory drugs.
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Kasper, Dennis L., et al., editors. "MOOD-STABILIZING AGENTS." Harrison's Manual of Medicine, 20th ed., McGraw Hill Inc., 2020. harrisons.unboundmedicine.com/harrisons/view/Harrisons-Manual-of-Medicine/623739/all/MOOD_STABILIZING_AGENTS.
MOOD-STABILIZING AGENTS. In: Kasper DLD, Fauci ASA, Hauser SLS, et al, eds. Harrison's Manual of Medicine. McGraw Hill Inc.; 2020. https://harrisons.unboundmedicine.com/harrisons/view/Harrisons-Manual-of-Medicine/623739/all/MOOD_STABILIZING_AGENTS. Accessed October 10, 2024.
MOOD-STABILIZING AGENTS. (2020). In Kasper, D. L., Fauci, A. S., Hauser, S. L., Longo, D. L., Jameson, J. L., & Loscalzo, J. (Eds.), Harrison's Manual of Medicine (20th ed.). McGraw Hill Inc.. https://harrisons.unboundmedicine.com/harrisons/view/Harrisons-Manual-of-Medicine/623739/all/MOOD_STABILIZING_AGENTS
MOOD-STABILIZING AGENTS [Internet]. In: Kasper DLD, Fauci ASA, Hauser SLS, Longo DLD, Jameson JLJ, Loscalzo JJ, editors. Harrison's Manual of Medicine. McGraw Hill Inc.; 2020. [cited 2024 October 10]. Available from: https://harrisons.unboundmedicine.com/harrisons/view/Harrisons-Manual-of-Medicine/623739/all/MOOD_STABILIZING_AGENTS.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - MOOD-STABILIZING AGENTS
ID - 623739
ED - Jameson,J Larry,
ED - Loscalzo,Joseph,
ED - Kasper,Dennis L,
ED - Fauci,Anthony S,
ED - Hauser,Stephen L,
ED - Longo,Dan L,
BT - Harrison's Manual of Medicine
UR - https://harrisons.unboundmedicine.com/harrisons/view/Harrisons-Manual-of-Medicine/623739/all/MOOD_STABILIZING_AGENTS
PB - McGraw Hill Inc.
ET - 20
DB - Harrison's Manual of Medicine
DP - Unbound Medicine
ER -